Clarifying the dilemmas about inhalation techniques for dry powder inhalers: Integrating science with clinical practice

Primary Care Respiratory Journal

Volumn 21, Issue 2, 2012, Pages 208-213

  Azouz, Wahida ^a   Chrystyn, Henry ^a  

^a UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Dry powder inhaler; Inhalation manoeuvre

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

AIRFLOW; AIRWAY DYNAMICS; AIRWAY RESISTANCE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; EQUIPMENT DESIGN; EXHALATION; HUMAN; INHALATION; INHALATION SPACER; INHALATIONAL MANEUVER; LUNG FUNCTION; PATIENT EDUCATION; POWDER INHALER; PRACTICE GUIDELINE; REVIEW;

ADMINISTRATION, INHALATION; DRY POWDER INHALERS; HUMANS; RESPIRATORY MECHANICS;

EID: 84862644228     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2012.00010     Document Type: Review

References (35)

1. Laube BL, Janssens HM, de Jongh FHC, et al. ERS/ISAM Task Force Consensus Statement: Recommendations on what the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37:1308-31. http://dx.doi.org/10.1183/09031936.00166410
2. Broeders MEAC, Vincken W, Corbetta L. Ways to improve pharmacological management of COPD: the importance of inhaler choice and inhalation technique. Prim Care Respir J 2011;20:338-43. http://dx.doi.org/10.4104/pcrj.2011.00062
3. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling on inhalers in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003;16:249-54. http://dx.doi.org/10.1089/ 089426803769017613
4. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008;102:593-604. http://dx.doi.org/10.1016/j.rmed.2007.11.003
5. Melani AS, Bonavia M, Cilenti V, et al., on behalf of the Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri (AIPO). Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105:930-8. http://dx.doi.org/10.1016/j.rmed.2011.01.005
6. Chrystyn H. Effects of device design on patient compliance: comparing the same drug in different devices. In: Dalby RN, Byron PR, Peart J, Suman JD, Young PM, eds. Respiratory Drug Delivery Europe 2009. Volume 1. Richmond, VA, USA: Davis Healthcare International Publishing, Virginia Commonwealth University, 2009, p.105-16.
7. Chrystyn H. Is inhalation rate important for dry powder inhalers? Using the In-Check Dial to identify these rates. Respir Med 2003;97:181-18. http://dx.doi.org/ 10.1053/rmed.2003.1351
8. Chrystyn H. Closer to an 'Ideal Inhaler' with the Easyhaler: An Innovative Dry Powder Inhaler. Clin Drug Invest 2006;26(4):175-83. http://dx.doi.org/10.2165/00044011-200626040-00001
9. Prime D, Slater AL, Haywood PA Smith IJ. Assessing dose delivery from the Flixotide Diskus Inhaler-a multidose powder inhaler. Pharmaceutical Technology Europe 1996;8(3):23-34.
10. G Persson, E Gruvstad, E Stahl. A new multiple dose powder inhaler, (Turbuhaler), compared with a pressurized inhaler in a study of terbutaline in asthmatics. Eur Respir J 1988;1:681-4.
11. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers: implications for in vitro testing. J Aerosol Med 1993;6:99-110. http://dx.doi.org/10.1089/jam.1993.6.99
12. Broeders MEAC, Molama J, Hop WCJ, Folgering HTM. Inhalation profiles in asthma and COPD patients: reproducibility and effect of instruction. J Aerosol Med 2003;16:131-41. http://dx.doi.org/10.1089/089426803321919898
13. Palander A, Mattila T, Karka M, Muttonen E. In-vitro comparison of three salbutamolcontaining multidose dry powder inhalers. Clin Drug Invest 2000;20:25-33. http://dx.doi.org/10.2165/00044011-200020010-00004
14. Borgstrom L. On the use of dry powder inhalers in situations perceived as constrained. J Aerosol Med 2001;14:281-7. http://dx.doi.org/10.1089/ 089426801316970231
15. Nadarassan DK, Assi KH, Chrystyn H. Aerodynamic characteristics of a dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen Cascade Impactor. Eur J Pharm Sci 2010;39:348-54. http://dx.doi.org/10.1016/ j.ejps.2010.01.002
16. Pedersen S, Hansen R, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990;65:308-19. http://dx.doi.org/10.1136/ adc.65.3.308
17. Nielsen KG, Auk IL, Bojsen K, Ifversen M, Klug B, Bisgaard H. Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow rates in asthmatic children. Eur Respir J 1998;11:350-4. http://dx.doi.org/10.1183/09031936.98.11020350
18. Koskela T, Malmström K, Sairanen U, Peltol, S, Keski-Karhu J, Silvasti M. Efficacy of salbutamol via Easyhaler unaffected by low inspiratory flow. Respir Med 2000;94:1229-33. http://dx.doi.org/10.1053/rmed.2000.0959
19. Newman SP, Pitcairn GR, Adkin DA, Vidgren MT, Silvasti M. Comparison of beclomethasone dipropionate delivery by Easyhaler dry powder inhaler and pMDI plus large volume spacer. J Aerosol Med 2001;14:217-25. http://dx.doi.org/10.1089/08942680152484144
20. Thomas M, Price D, Chrystyn H, Lloyd A, Williams AE, von Ziegenwich J. Inhaled corticosteroids for asthma: Impact of practice-level device switching on asthma control. BMC Pulm Med 2009;9:1. http://dx.doi.org/10.1186/1471-2466-9-1
21. Pedersen S, Dubus JC, Crompton GK; ADMIT Working Group. The ADMIT series. Issues in inhalation therapy. (5) Inhaler selection in children with asthma. Prim Care Respir J 2010;19:209-16. http://dx.doi.org/10.4104/pcrj.2010.00043
22. Al-Showair RAM, Tarsin WY, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med 2007;101:2395-401. http://dx.doi.org/10.1016/j.rmed.2007.06.008
23. Broeders ME, Molema J, Hopp WC, Vermue NA, Folgering HT. The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir Med 2004;98:1173-9. http://dx.doi.org/10.1016/j.rmed.2004.04.010
24. Clark A. Effect of powder inhaler resistance upon inspiratory profiles in health and disease. In: Byron PR, Dalby RN, Farr SJ, eds. Respiratory Drug Delivery IV. Volume 1. Buffalo Grove, IL, USA: Interpharm Press, 1994, p.117-23.
25. De Boer AH, Bolhuis GK, Gjaltema D, Hagedoorn P. Inhalation characteristics and their effect on the in-vitro drug delivery from dry powder inhalers. Int J Pharm 1997;153:67-77. http://dx.doi.org/10.1016/S0378-5173(97)00097-5
26. Chrystyn H, Price D. What you need to know about inhalers and how to use them. Prescriber 2009; Issue 12: 47-52.
27. Broeders ME, Molema J, Vermue NA, Folgering HT. Peak inspiratory flow rate and the slope of the inhalation profiles in dry powder inhalers. Eur Respir J 2001;18:780-3. http://dx.doi.org/10.1183/09031936.01.00240301
28. Lavorini F, Levy ML, Corrigan C, Crompton G; ADMIT Working Group. The ADMIT series. Issues in inhalation therapy. (6) Training tools for inhalation devices. Prim Care Respir J 2010;19:335-41. http://dx.doi.org/10.4104/pcrj.2010.00065
29. Alaboud A, Assi KH, Chrystyn H. In vitro characterization of the emitted dose from the Foradil aerolizer to identify the influence of inhalation flow, inhalation volume and the number of inhalations per dose. In: Dalby RN, Byron PR, Peart J, Suman JD, Young PM, eds. Respiratory Drug Delivery 2010. Volume 3. Richmond, VA, USA: Davis Healthcare International Publishing, Virginia Commonwealth University, 2010, p.803-6.
30. Kamin WES, Genz T, Roeder S, Scheuch G, Trammer T, Juenemann R, Cloes RM. Mass output and particle size distribution of glucocorticosteroids from different inhalation devices depending on various inspiratory parameters. J Aerosol Med 2002;15:65-73. http://dx.doi.org/10.1089/08942680252908593
31. Derom E, Strandgarden K, Schelfhout V, Borgstrom L, Pauwels R. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD. Respir Med 2007;101:1931-41. http://dx.doi.org/10.1016/j.rmed.2007.04.013
32. Hindle M, Newton DAG, Chrystyn H. Investigations of an optimal inhaler technique using urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax 1993;48:607-11. http://dx.doi.org/10.1136/thx.48.6.607
33. Meakin BJ, Cainey JM, Woodcock PM. Simulated 'in-use' and 'mis-use' aspects of the delivery of terbutaline sulphate from Bricanyl Turbohaler™ dry powder inhalers. Int J Pharm 1995;119:103-08. http://dx.doi.org/10.1016/0378-5173(94)00388-L
34. Lavorini F, Corbetta L, on behalf of the Aerosol Drug Management Improvement Team (ADMIT). Achieving asthma control: the key role of inhalers. Breathe 2008;5:121-31.
35. van der Palen J, Klein JJ, van Herwaarden CL, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J 1999;14:1034-7. http://dx.doi.org/ 10.1183/09031936.99.14510349